DDY391

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Moderate to Severe Psoriatic ArthritisSjögren's Disease

Phase 2

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

RecruitingNCT07737743

Novartis PharmaceuticalsSjögren's Disease

Start: 2026-08-24End: 2029-03-19Target: 344Updated: 2026-09-09

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

RecruitingNCT07801495

Novartis PharmaceuticalsModerate to Severe Psoriatic Arthritis

Start: 2026-10-14End: 2029-01-12Target: 220Updated: 2026-09-17